Compare PHAT & CRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAT | CRI |
|---|---|---|
| Founded | 2018 | 1865 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.6M | 1.0B |
| IPO Year | 2019 | 2003 |
| Metric | PHAT | CRI |
|---|---|---|
| Price | $14.36 | $31.95 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 4 |
| Target Price | $17.33 | ★ $29.50 |
| AVG Volume (30 Days) | 828.8K | ★ 963.5K |
| Earning Date | 10-30-2025 | 10-27-2025 |
| Dividend Yield | N/A | ★ 3.15% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.45 |
| Revenue | $147,190,000.00 | ★ $2,832,687,000.00 |
| Revenue This Year | $218.59 | $1.58 |
| Revenue Next Year | $84.38 | $0.14 |
| P/E Ratio | ★ N/A | $12.94 |
| Revenue Growth | ★ 460.30 | N/A |
| 52 Week Low | $2.21 | $23.38 |
| 52 Week High | $16.27 | $58.13 |
| Indicator | PHAT | CRI |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 53.31 |
| Support Level | $14.12 | $31.00 |
| Resistance Level | $16.27 | $32.67 |
| Average True Range (ATR) | 0.72 | 1.24 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 8.39 | 81.76 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.